
Please try another search
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA)...
On Thursday, 29 May 2025, Moderna Inc. (NASDAQ:MRNA) presented at the Bernstein 41st Annual Strategic Decisions Conference 2025. The discussion, led by CEO Stephane Bancel, highlighted Moderna's...
CAMBRIDGE, MA - Moderna, Inc. (NASDAQ:MRNA), the $10 billion biotech company whose shares have declined over 37% year-to-date, has disclosed positive interim data from its Phase 1/2 study assessing...
Moderna , Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza...
CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Jefferies Global Health Care...
Moderna , Inc. (NASDAQ:MRNA), a biotechnology company renowned for its messenger RNA (mRNA) technology platform with a current market capitalization of $10.16 billion, stands at a critical juncture...
CAMBRIDGE, MA - Moderna, Inc. (NASDAQ:MRNA), currently valued at $10.2 billion, has announced its submission of an updated COVID-19 vaccine formula, Spikevax 2025-2026, for review by the U.S. Food and...
Moderna , Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review